Skip to main content
    V

    Vaxcyte Inc (PCVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $61.61
    -1.76 (-2.78%)

    Market Cap: $10.03B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Vaxcyte Inc (PCVX) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Vaxcyte (PCVX) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Vaxcyte reported EPS of -$1.99, below the -$1.84 estimate. It beat the EPS estimate in 0 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    41%(11/27)
    Avg Surprise
    -2.16%

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$2.01
    Range-$2.70 - -$0.90
    12 analysts
    Revenue Consensus
    N/A
    RangeN/A
    12 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.51
    Range-$2.00 - -$0.97
    3 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$1.32-14.1%
    60d ago-$1.32-14.1%
    30d ago-$1.32-14.1%
    7d ago-$1.54+2.0%
    Current-$1.51
    Revenue Consensus
    N/A
    RangeN/A
    5 analysts

    Next Report

    PCVX has an expected report date of Feb 22, 2027.

    PCVX Earnings Call

    The latest PCVX earnings call transcript on file is labeled 2025Q4.

    Read the 2025Q4 transcript

    Earnings History

    Of the 27 quarters below that had an estimate, PCVX beat 11 and missed 16. The widest gap in the table came in the quarter ended Mar 31, 2020, when EPS landed 94.06% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$1.99-$1.84-$2.68 - -$1.67-8.15%MissN/A72 up, 0 downNov 4, 2026
    Jun 30, 2026-$1.97-$1.47-$2.55 - -$1.47-34.01%MissN/A70 up, 0 downAug 5, 2026
    Mar 31, 2026-$2.30-$1.77-$1.96 - -$1.58-29.94%MissN/A51 up, 1 downMay 6, 2026
    Dec 31, 2025-$1.80-$1.47-$1.90 - -$1.12-22.45%MissN/A60 up, 3 downFeb 24, 2026
    Sep 30, 2025-$1.56-$1.24-$1.52 - -$1.00-25.81%MissN/A61 up, 1 downNov 4, 2025
    Jun 30, 2025-$1.22-$1.16-$1.29 - -$1.01-5.17%MissN/A50 up, 0 downAug 6, 2025
    Mar 31, 2025-$1.04-$0.97-$1.14 - -$0.81-7.22%MissN/A20 up, 0 downMay 7, 2025
    Dec 31, 2024-$1.02-$0.99-$1.15 - -$0.91-2.58%MissN/A5N/AFeb 25, 2025
    Sep 30, 2024-$0.83-$0.99-$1.35 - -$0.88+16.16%BeatN/A81 up, 0 downNov 5, 2024
    Jun 30, 2024-$1.10-$1.00-$1.10 - -$0.86-10.00%MissN/A80 up, 0 downAug 6, 2024
    Mar 31, 2024-$0.85-$1.06-$1.72 - -$0.84+19.81%BeatN/A80 up, 0 downMay 8, 2024
    Dec 31, 2023-$1.82-$1.07-$1.61 - -$0.54-70.09%MissN/A80 up, 0 downFeb 27, 2024
    Sep 30, 2023-$0.91-$0.84-$0.96 - -$0.73-8.33%MissN/A80 up, 0 downNov 6, 2023
    Jun 30, 2023-$0.70-$0.77-$0.86 - -$0.61+9.09%BeatN/A80 up, 0 downAug 8, 2023
    Mar 31, 2023-$0.70-$0.88-$0.97 - -$0.76+20.45%BeatN/A70 up, 0 downMay 8, 2023
    Dec 31, 2022-$1.02-$0.93-$1.20 - -$0.78-9.68%MissN/A70 up, 2 downFeb 27, 2023
    Sep 30, 2022-$0.93-$0.85-$0.86 - -$0.80-9.41%MissN/A30 up, 0 downNov 7, 2022
    Jun 30, 2022-$0.80-$0.66N/A-21.21%MissN/AN/A0 up, 0 downAug 8, 2022
    Mar 31, 2022-$0.68-$0.66-$0.75 - -$0.56-3.03%MissN/A30 up, 0 downMay 9, 2022
    Dec 31, 2021-$0.55-$0.56-$0.62 - -$0.50+1.79%BeatN/A30 up, 0 downFeb 28, 2022
    Sep 30, 2021-$0.51-$0.58-$0.59 - -$0.47+12.07%BeatN/A33 up, 0 downNov 10, 2021
    Jun 30, 2021-$0.46-$0.53-$0.58 - -$0.46+13.21%BeatN/A3N/AAug 11, 2021
    Mar 31, 2021-$0.41-$0.56-$0.56 - -$0.41+26.79%BeatN/A2N/AMay 11, 2021
    Dec 31, 2020-$0.41-$0.54-$0.60 - -$0.46+24.07%BeatN/A3N/AMar 29, 2021
    Sep 30, 2020-$0.41-$0.44-$0.48 - -$0.42+6.82%BeatN/A3N/ANov 12, 2020
    Jun 30, 2020-$1.72-$1.27-$2.05 - -$0.66-35.43%MissN/A3N/AAug 12, 2020
    Mar 31, 2020-$0.29-$4.88N/A+94.06%BeatN/AN/AN/AJun 15, 2020
    Dec 31, 2019-$1.08N/AN/AN/AN/AN/AN/AN/AMar 30, 2020
    Last 28 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$5.62, after -$3.80 the year before. It was -$1.08 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$5.62N/A
    Dec 31, 2024-$3.80N/A
    Dec 31, 2023-$4.13N/A
    Dec 31, 2022-$3.43N/A
    Dec 31, 2021-$1.93N/A
    Dec 31, 2020-$2.83N/A
    Dec 31, 2019-$1.08N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 7,900 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q4Dec 31, 20257,91115
    2024Q4Dec 31, 20248,68111

    2025Q4 Earnings Call

    Opening remarks

    Andrew Guggenhime President and CFO Thank you, operator. Good afternoon, everyone, and thanks for joining us today as we review our 2025 results and provide a business update. I am joined by our Chief Executive Officer, Grant Pickering; and our Executive Vice President and Chief Operating Officer, Jim Wassil. Earlier today, we issued a news release announcing our results. Copies of this and our other news releases, latest corporate presentation and SEC filings can be found in the Investors and Media section of our website. Before we begin, I'd like to remind you that during this call, we'll be making certain forward-looking statements about Vaxcyte, which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in any forward-looking statements. For a discussion of the risks and uncertainties associated with these statements, please see our press release issued today as well as our most recent filings with the SEC, including the risk factors set forth in our Form 10-K for the year ended December 31, 2025, and any subsequent reports filed with the SEC. With that, I'll turn the call over to Grant Pickering. Grant?

    Grant Pickering CEO Thanks, Andrew. As we close out 2025 and look forward to multiple clinical readouts beginning later this year, I'm proud of the progress we made across the company, particularly within our pneumococcal conjugate vaccine or PCV franchise. Despite decades of vaccination efforts, pneumococcal disease continues to drive substantial morbidity and mortality worldwide, particularly among young children and older adults. While current vaccines have made a meaningful impact, gaps in serotype coverage persist and the public health need for broader spectrum protection remains clear. Consistent with that need, we are seeing accelerating growth in the adult PCV market, driven by expanded age group recommendations in the United States and increasing international adoption of adult PCV vaccination. Continued momentum in the PCV class has reinforced the size of the opportunity and demand for a PCV that increases disease coverage by protecting against both historically and currently circulating serotypes while maintaining robust immune responses. Taken together, this underscores our opportunity to improve public health as we prepare to enter an increasingly attractive commercial market. The unprecedented results from our Phase II study in adults demonstrated that VAX-31 may offer substantial improvement over existing products and achieve our objective to significantly expand disease coverage while maintaining high immunogenicity responses. And with the OPUS Phase III program underway, we believe that we are uniquely positioned to set a new standard by which future adult pneumococcal vaccines will be measured.

    Frequently Asked Questions About PCVX

    When is Vaxcyte's next earnings date?

    Vaxcyte's next earnings report is expected for Feb 22, 2027.

    Did PCVX beat earnings estimates last quarter?

    No. Vaxcyte reported EPS of -$1.99 for the quarter ended Sep 30, 2026, below the -$1.84 estimate by 8.15%.

    What EPS do analysts expect from PCVX next quarter?

    The consensus EPS estimate for Vaxcyte for the quarter ending Dec 31, 2026 is -$2.01 from 12 analysts, with estimates from -$2.70 to -$0.90.

    How often does PCVX beat earnings estimates?

    Vaxcyte beat the EPS estimate in 0 of the last 8 quarters, with an average surprise of -16.92%.